Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been given a consensus recommendation of “Moderate Buy” by the six analysts that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $57.50.

Several research firms have commented on COLL. Weiss Ratings cut shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 5th. Truist Financial set a $58.00 price objective on Collegium Pharmaceutical in a report on Tuesday, February 10th. HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of Collegium Pharmaceutical in a report on Friday, March 20th. Needham & Company LLC restated a “buy” rating and set a $56.00 price objective (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday, March 19th. Finally, Wall Street Zen upgraded Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ:COLL opened at $34.40 on Wednesday. The business’s fifty day moving average price is $33.88 and its two-hundred day moving average price is $40.72. The stock has a market cap of $1.12 billion, a PE ratio of 16.86 and a beta of 0.74. The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.62 and a current ratio of 1.71. Collegium Pharmaceutical has a one year low of $29.08 and a one year high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. The firm had revenue of $193.52 million for the quarter, compared to analysts’ expectations of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.Collegium Pharmaceutical’s quarterly revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.49 EPS. On average, analysts forecast that Collegium Pharmaceutical will post 6.76 EPS for the current fiscal year.

Insider Activity

In other news, EVP David Dieter sold 13,976 shares of the firm’s stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total transaction of $488,041.92. Following the sale, the executive vice president owned 77,071 shares in the company, valued at $2,691,319.32. This trade represents a 15.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.85% of the stock is owned by company insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

Several hedge funds have recently made changes to their positions in COLL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Collegium Pharmaceutical by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock worth $569,000 after purchasing an additional 825 shares during the last quarter. Millennium Management LLC raised its position in shares of Collegium Pharmaceutical by 248.5% in the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after buying an additional 461,914 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Collegium Pharmaceutical by 7.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company’s stock worth $2,120,000 after buying an additional 4,625 shares during the period. Jane Street Group LLC raised its position in shares of Collegium Pharmaceutical by 218.7% in the 1st quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock worth $3,926,000 after buying an additional 90,255 shares during the period. Finally, JPMorgan Chase & Co. raised its position in shares of Collegium Pharmaceutical by 3.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 72,068 shares of the specialty pharmaceutical company’s stock worth $2,131,000 after buying an additional 2,592 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.